H.C. Wainwright initiated coverage of BioMarin (BMRN) with a Neutral rating and $60 price target The firm sees “looming risk” for Voxzogo from oral FGFR inhibitors. The inhibitors could erode Voxzogo’s market share despite strong uptake to date, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin announces Phase 3 data for PALYNZIQ
- BioMarin initiated with an Outperform at Raymond James
- AI Analyst Is Bullish on These 3 “Strong Buy” Healthcare Stocks, 9/2/25
- BioMarin Announces Resignation of Chief Accounting Officer
- Positive Outlook on BioMarin Pharmaceutical: Strong Financials and Promising Pipeline Drive Buy Rating